---
url: https://www.servicesaustralia.gov.au/severe-growth-failure-with-primary-insulin-growth-factor-1-deficiency
title: Severe growth failure with primary insulin-like growth factor-1 deficiency - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:41:47.967Z
source: servicesaustralia.gov.au
---
# Severe growth failure

The PBS subsidises mecasermin for patients with severe growth failure with primary insulin-like growth factor-1 deficiency (IGFD).

## on this page

-   [Patient eligibility](#a1)
-   [Section 100 arrangements](#a2)
-   [Treatment specifics](#a3)
-   [Authority applications](#a4)
-   [More information](#a5)

Please note: Youâ€™ll get an immediate assessment when you request [PBS authorities online](/apply-for-pbs-authority?context=20#accordion1).

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with mecasermin under the _National Health Act 1953_, section 100 for patients aged 2 to 17 years old (inclusive) with severe growth failure with primary insulin-like growth factor-1 deficiency (IGFD).

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](https://www.pbs.gov.au/pbs/home) on the PBS website outlines the restrictions for prescribing mecasermin.

## Section 100 arrangements

### Mecasermin

This item is PBS-subsidised under Section 100 Growth Hormone Program and can be dispensed by a:

-   community pharmacy
-   participating PBS reform public hospital pharmacy
-   private hospital pharmacy
-   dispensing doctor.

## Treatment specifics

To be eligible for PBS-subsidised treatment with mecasermin, patients must be treated by and the medication must be prescribed by either:

-   a paediatric endocrinologist
-   a paediatrician in consultation with a paediatric endocrinologist.

## Authority applications

### Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised mecasermin to treat severe growth failure with primary IGFD can be made either in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include the completed:

-   authority prescription form or forms
-   [severe growth failure with primary insulin-like growth factor-1 deficiency - mecasermin - initial authority application form](/pb336?context=20)
-   relevant attachments.

### Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised mecasermin to treat severe growth failure with primary IGFD can be made either in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include the completed:

-   authority prescription form or forms
-   [severe growth failure with primary insulin-like growth factor-1 deficiency - mecasermin - continuing authority application form](/pb337?context=20)
-   relevant attachments.

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.
